Table 5.
Univariable analysis of the prognostic significance of BAF250a, MMR, and p53
|
Overall survival
|
Progression-free survival
|
|||
|---|---|---|---|---|
| Hazard ratio | P | Hazard ratio | P | |
| Entire cohort (n = 190) | ||||
| BAF250a loss | 0.67 | 0.27 | 0.25 | 0.011 |
| MMR deficiency | 0.5 | 0.0315 | 0.43 | 0.023 |
| p53 aberrant | 1.67 | 0.0418 | 1.75 | 0.055 |
| Endometrioid (n = 82) | ||||
| BAF250a loss | 0.94 | 0.917 | 0.42 | 0.28 |
| MMR deficiency | 0.7 | 0.483 | 2.5 | 0.231 |
| p53 aberrant | 1.32 | 0.612 | 0.61 | 0.554 |
| Serous (n = 89) | ||||
| BAF250a loss | 0.48 | 0.234 | 0.34 | 0.268 |
| MMR deficiency | 0.54 | 0.251 | 0.23 | 0.117 |
| p53 aberrant | 2.34 | 0.0528 | 1.64 | 0.305 |